Press Releases April 20, 2026 04:05 PM

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation announces inducement stock option grants to nine new employees under Nasdaq rules

By Caleb Monroe GERN

Geron Corporation, a biopharmaceutical company, reported the granting of stock options totaling 855,000 shares to nine newly hired employees as inducements to join the firm. The options, priced at $1.68 per share, vest over four years and align with Nasdaq Listing Rule 5635(c)(4). Geron continues its efforts with its approved drug RYTELO® for blood cancers and ongoing pivotal Phase 3 trials.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GERN

Key Points

  • Geron granted stock options for 855,000 shares to nine new employees as inducements.
  • Options have a $1.68 exercise price, ten-year term, and four-year vesting schedule.
  • Geron is a commercial-stage biopharmaceutical firm with an approved drug and ongoing clinical trials in blood cancers.

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.68 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]


Risks

  • The inducement awards depend on continued employment, creating retention risk if employees depart early.
  • The stock options issued could dilute existing shareholders when exercised, potentially impacting the stock price.
  • Uncertainties around the clinical trial outcomes for imetelstat in myelofibrosis could affect future company prospects.

More from Press Releases

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease May 19, 2026 Inno Holdings Inc. Announces $60.0 Million “At-the-Market” Equity Offering Program May 19, 2026 Northrop Grumman Board Declares Quarterly Dividend May 19, 2026 NOVAGOLD Announces Election of Directors and Voting Results from 2026 Virtual Annual General Meeting of Shareholders May 19, 2026 Diana Shipping Inc. Releases Investor Presentation Highlighting Need for Change at Genco Shipping & Trading May 19, 2026